Catalyst

Slingshot members are tracking this event:

Phase 2b data of MN-166 for Progressive multiple sclerosis (progressive MS) due Oct 28 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MNOV

100%

Additional Information

Additional Relevant Details Update on Aug 30 2017: Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France
http://investors.med...
Clinical Data Update on Oct 30 2017:Primary Endpoint #1: MN-166 (ibudilast) demonstrated a statistically significant 48% reduction in the rate of progression of whole brain atrophy compared to placebo (p=0.04) as measured by MRI analysis using brain parenchymal fraction (BPF).Primary Endpoint #2: MN-166 (ibudilast) demonstrated a favorable safety and tolerability profile. There was not an increased rate of serious adverse events in the MN-166 (ibudilast) group compared to the placebo group. There were no opportunistic infections, no cancers, no cardiovascular events (i.e. no heart attacks or strokes), and no deaths related to MN-166 (ibudilast) treatment, as determined by an Independent Medical Monitor. There was no statistically significant difference in tolerability between the MN-166 (ibudilast) group and the placebo group. The most common treatment-emergent adverse events during the study were gastrointestinal adverse events, which occurred with a higher frequency in the MN-166 (ibudilast) group, and upper respiratory tract infections, which occurred with a higher frequency in the placebo group.
http://investors.med...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 26, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b Data, Mn-166, Progressive Multiple Sclerosis, Progressive Multiple Sclerosis